Asia Pacific Urinalysis Market is expected to reach US$ 1,411.47 million by 2028

PRESS RELEASE BY The Insight Partners 15 Dec 2021

Share this press on

Disease Screening Urinalysis Segment to Dominate APAC Urinalysis Market during 2020–2028      

According to The Insight Partners market research study on “APAC Urinalysis Market to 2028 – COVID-19 Impact and Regional Analysis and Forecast by Product, Test Type, Application, End User” is expected to reach US$ 1,411.47 million by 2028 from 917.20 US$ million in 2021. The market is estimated to grow at a CAGR of 6.4% from 2021 to 2028. The report provides trends prevailing in the APAC urinalysis market along with the drivers and restraints pertaining to the market growth. Market players are launching more products and implementing more strategic initiatives, and this is the major factor driving the growth of the APAC urinalysis market. However, issues associated with product recalls and tough regulatory requirements hinders the growth of APAC urinalysis market.  

APAC urinalysis market is segmented into product, test type, application, end user, and country. Based on product, the APAC urinalysis market is segmented into consumables and instruments. The consumables segment is expected to hold a larger market share in 2021. The APAC urinalysis market, based on test type, is segmented into pregnancy and fertility tests, biochemical urinalysis, and sediment urinalysis. The biochemical urinalysis segment would hold the largest share of the market in 2021. Based on application, the APAC urinalysis market is segmented into disease screening and pregnancy, and fertility. The disease screening segment would account for a larger market share in 2021. The APAC urinalysis market, by end user, is segmented into hospitals and clinics, diagnostic laboratories, home care settings, and research laboratories and institutes. The hospitals and clinics segment would hold the largest share of the market in 2021. Based on country, the APAC urinalysis market is segmented into Australia, China, India, Japan, South Korea, and rest of APAC. China held the largest market share in 2021.

The COVID-19 pandemic affected most programs in APAC, but to varying degrees. Medical device manufacturers and suppliers are shifting their focus on supplying essentials and medical devices related to the management of COVID-19. The shift in focus toward pandemic has disrupted the spectrum of kidney and renal care, including delayed diagnoses and treatment, and disrupted clinical trials. In response, healthcare systems are rapidly reorganizing cancer services to ensure that patients receive essential care while minimizing exposure to SARS-CoV-2 infection. Diagnostic testing service providers are coordinating with healthcare authorities to manage testing services residues, prioritize testing services, and use modern technology to overcome potential barriers. The increased adoption of at-home settings for urinalysis for the diagnosis of diseases such as UTIs, and other renal and kidney diseases tests also helped fill the gaps in screening. The transport restrictions imposed by various countries have had a major influence on international trade and commerce. India, too, has suffered owing to unexpected economic disruptions caused by interim restrictions on public activities and regional lockdowns. Asia’s value chains have closely integrated the economies of China, Japan, South Korea, Hong Kong, and other Asian countries. Such dense and extremely coordinated value chains enable massive economies of scale in manufacturing.

Abbott; ACON Laboratories, Inc.; ARKRAY, Inc.; Beckman Coulter, Inc.; Bio-Rad Laboratories Inc.;        Cardinal Health Inc; F. Hoffmann-La Roche Ltd.; Quidel Corporation; Siemens Healthineers AG; and         Sysmex Corporation are among the leading companies in the APAC urinalysis market. The companies are focused on adopting organic growth strategies such as product launches and expansions to sustain their position in the dynamic market. For instance, ARKRAY, Inc. launched its "AUTION EYE AI-4510" on July 8, 2019. The urine sediment analyzer has compact design that enable its installation even in labs with limited space. It uses a flow-type image measurement method to capture images of formed elements inside urine samples, then extracts, analyzes, categorizes, and measures those formed element images, and then provides urine sediment test data. It supports a full series of urine testing processes, thereby contributed to the improved efficiency of testing operations.    

Contact Us
Phone: +1-646-491-9876
Email Id:

Download Free PDF Brochure